Pregnancy cat. ?
Legal status Prescription only
Routes Nasal muscosa
Synonyms Selanc; L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-Proline
Cеланк) is a nootropic,
drug developed by the Institute of Molecular Genetics of the Russian academy of
sciences. Selank is a heptapeptide with the sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analogue of a human tetrapeptide
Selank is a synthetic analogue of the immunomodulatory
as such, it mimics many of its effects. It has been shown to modulate the
expression of Interleukin-6 (IL-6) and affect the balance of T
helper cell cytokines.
It is has been shown to influence the concentration of monoamine neurotransmitters and induce
metabolism of serotonin. There is
evidence that it may also modulate the expression of Brain-derived neurotropic factor
(BDNF) in rats.
In clinical trials, the drug has shown to provide a
sustained nootropic and anxioytic effect, which is useful for the treatment of generalized anxiety disorder (GAD).
Selank has an advantage over traditional anxiety treatments, such as benzodiazepines,
as it has no sedating
or cognitive side effects and no associated addiction or
withdrawal syndrome. Selank also has very low toxicity with an overdose proving
harmless even up to 500 times the effective dose. When released, the drug will
be used as a 0.15% aqueous solution which is applied to the nasal mucosa in
drops. It is thought that this is the best method for absorbing peptide based
drugs. The drug can be used to suppress feelings of fear and anxiety in people
with anxiety disorders and to stimulate learning and memory in healthy people.
As of 2010, the drug has completed stage III clinical
trials in Russia and is currently waiting to be authorized for general use in
that region. It is unknown
if the drug will be marketed in the West or other world regions at this stage.
Selank is closely related to another nootropic drug,
Semax, also developed by the Institute of Molecular Genetics in Russia. This
drug is currently available in Russian and Ukrainian pharmacies.
1. ^ a
Uchakina, ON; Uchakin, PN; Miasoedov, NF; Andreeva, LA; Shcherbenko, VE;
Mezentseva, MV; Gabaeva, MV; Sokolov, OIu et al. (2008). "Immunomodulatory
effects of selank in patients with anxiety-asthenic disorders". Zhurnal
nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia
i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo
nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 108 (5): 71–5. PMID 18577961. edit
2. ^ Narkevich, VB; Kudrin, VS; Klodt,
PM; Pokrovskiĭ, AA; Kozlovskaia, MM; Maĭskiĭ, AI; Raevskiĭ, KS (2008).
"Effects of heptapeptide selank on the content of monoamines and their
metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study".
Eksperimental'naia i klinicheskaia farmakologiia 71 (5): 8–12. PMID 19093364. edit
3. ^ Semenova, TP; Kozlovskiĭ, II;
Zakharova, NM; Kozlovskaia, MM (2010). "Experimental optimization of
learning and memory processes by selank". Eksperimental'naia i
klinicheskaia farmakologiia 73 (8): 2–5. PMID 20919548. edit
4. ^ Inozemtseva, LS; Karpenko, EA;
Dolotov, OV; Levitskaya, NG; Kamensky, AA; Andreeva, LA; Grivennikov, IA
(2008). "Intranasal administration of the peptide Selank regulates BDNF
expression in the rat hippocampus in vivo". Doklady biological
sciences : proceedings of the Academy of Sciences of the USSR, Biological
sciences sections / translated from Russian 421: 241–3. PMID 18841804. edit
5. ^ Institute of Molecular Gentics: Translation